Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice

Infection and Immunity

Volumn 71, Issue 9, 2003, Pages 5178-5187

  Su, Zhong ^a   Tam, Mi Fong ^a   Jankovic, Dragana ^b   Stevenson, Mary M ^a,c  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G2; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; INTERLEUKIN 4; MALARIA VACCINE; OLIGODEOXYNUCLEOTIDE; PARASITE ANTIBODY; PARASITE ANTIGEN; RECOMBINANT INTERLEUKIN 12;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CPG ISLAND; DRUG POTENCY; GENETIC SUSCEPTIBILITY; IMMUNOSTIMULATION; MALARIA; MOUSE; NONHUMAN; PLASMODIUM CHABAUDI; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL; TH1 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; B-LYMPHOCYTES; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; MALARIA; MALARIA VACCINES; MALE; MICE; MICE, INBRED A; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGODEOXYRIBONUCLEOTIDES; PLASMODIUM CHABAUDI; RECOMBINANT PROTEINS; TH1 CELLS;

EID: 0042825383     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.71.9.5178-5187.2003     Document Type: Article

References (49)

1. Alfonso, L. C. C., T. M. Scharton, L. Q. Vieira, M. Wysocka, G. Trinchieri, and P. Scott. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263:235-237.
2. Amante, F. H., and M. F. Good. 1997. Prolonged Th1-like response generated by a Plasmodium yoelii-specific T cell clone allows complete clearance of infection in reconstituted mice. Parasite Immunol. 19:111-126.
3. Artavanis-Tsakonas, K., and E. M. Riley. 2002. Innate immune response to malaria: rapid induction of IFN-γ from human NK cells by live Plasmodium falciparum-infected erythrocytes. J. Immunol. 169:2956-2963.
4. Braziolot-Millan, C. L., R. Weeratna, A. M. Krieg, C. A. Siegrist, and H. L. Davis. 1998. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. USA 95:1555-1558.
5. Davis, H. L., R. Weeratna, T. J. Waldschmidt, L. Tygrett, J. Schorr, and A. M. Krieg. 1998. CpG is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:870-876.
6. Deloran, P., C. Chougnet, J.-P. Lepers, S. Tallet, and P. Coulanges. 1991. Protective value of elevated levels of γ interferon in serum against exoerythrocytic stages of P. falciparum. J. Clin. Microbiol. 29:1757-1760.
7. Demi, L., R. Schirmheck, J. Reimann, H. Wolf, and R. Wagner. 1999. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV) gp160 envelope proteins. Clin. Chem. Lab. Med. 37:199-204.
8. DeSouza, J. B., K. H. Williamson, T. Otani, and J. H. Playfair. 1997. Early gamma interferon responses in lethal and nonlethal murine blood-stage malaria. Infect. Immun. 65:1593-1598.
9. Dodoo, D. F. Omer, J. Todd, B. Akanmori, K. Koram, and E. Riley. 2002. Absolute levels and ratios of pro-inflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to P. falciparum malaria. J. Infect. Dis. 185:971-979.
10. Facer, C. A., and M. Tanner. 1997. Clinical trials of malaria vaccines: progress and prospects. Adv. Parasitol. 39:1-68.
11. Favre, N., B. Ryffel, G. Bordmann, and W. Rudin. 1997. The course of Plasmodium chabaudi chabaudi infections in interferon-gamma receptor deficient mice. Parasite Immunol. 19:375-383.
12. Gately, M. K., L. M. Renzetti, J. Magram, A. S. Stern, L. Adorini, U. Gubler, and D. H. Presky. 1998. The interleukin-12/interleukin-12 receptor system: role in normal and pathogenic immune responses. Annu. Rev. Immmunol. 16:495-521.
13. Good, M. F. 2001. Towards a blood-stage vaccine for malaria: are we following all the leads? Nat. Rev. Immunol. 1:117-125.
14. Good, M. F., and D. L. Doolan. 1999. Immune effector mechanisms in malaria. Curr. Opin. Immunol. 11:412-419.
15. Gramzinski, R. A., D. L. Doolan, M. Sedegah, H. L. Davis, S. M. Krieg, and S. L. Hoffman. 2001. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect. Immun. 69:1643-1649.
16. Heinzel, F. P., R. M. Rerko, F. Ahmed, and A. M. Hujer. 1996. IFN-γ independent production of IL-12 during murine endotoxemia. J. Immunol. 157:4521-4528.
17. Holder, A. A. 1999. Malaria vaccines. Proc. Natl. Acad. Sci. USA 96:1167-1169.
18. James, S., and L. Miller. 2000. Malaria vaccine development: status report, p. 9-13. In Nature medicine special focus: malaria.
19. Jankovic, D., P. Caspar, M. Zweig, M. Garcia-Moll, S. D. Showalter, F. R. Vogel, and A. Sher. 1997. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J. Immunol. 159:2409-2417.
20. Jankovic, D., T. A. Wynn, M. C. Kullberg, S. Hieny, P. Caspar, S. James, A. W. Cheever, and A. Sher. 1999. Optimal vaccination against Schistosoma mansoni requires the induction of both B cell- and IFN-γ-dependent effector mechanisms. J. Immunol. 162:345-351.
21. Kenney, R. T., D. L. Sacks, J. P. Sypek, L. Vilela, A. A. Gam, and K. Evans-Davis. 1999. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol. 163:4481-4488.
22. Kitamura, D., J. Roes, R. Kühn, and K. Rajewsky. 1991. A B cell-deficient mouse by targeted disruption of the membrane exon on the immunoglobulin mu chain gene. Nature 350:423-426.
23. Klinman, D., A.-K. Yi, S. L. Beaucage, J. Conover, and A. M. Krieg. 1996. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFN-γ. Proc. Natl. Acad. Sci. USA 93:2879-2883.
24. Langhorne, J., S. J. Quin, and L. A. Sanni. 2002. Mouse models of blood-stage malaria infections: immune responses and cytokines involved in protection and pathology, p. 204-228. In P. Perlmann and M. Troye-Blomberg (ed.), Malaria immunology. Karger, Basel, Switzerland.
25. + T cells in the protective immune response to Plasmodium chabaudi in vivo. Immunol. Lett. 25:101-108.
26. Luty, A. J. F., B. Lell, R. Schmidt-Ott, L. G. Lehman, D. Luckner, B. Greve, P. Matousek, K. Herbich, D. Schmidt, F. Migot-Nabias, P. Deloran, R. S. Nussenzweig, and P. G. Kremnser. 1999. Interferon-γ responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J. Infect. Dis. 179:980-988.
27. Miller, M. A., M. J. Skeen, and H. K. Ziegler. 1997. A synthetic peptide administered with IL-12 elicits immunity to Listeria monocytogenes. J. Immunol. 159:3675-3679.
28. Mohan, K., P. Moulin, and M. M. Stevenson. 1997. Natural killer cell cytokine production, not cytotoxicity, contributes to resistance against blood-stage Plasmodium chabaudi AS infection. J. Immunol. 159:4990-5004.
29. Mohan, K., and M. M. Stevenson. 1998. Acquired immunity to asexual blood stages, p. 467-493. In I. W. Sherman (ed.), Malaria: parasite biology, pathogenesis, and protection. American Society Microbiology, Washington, D.C.
30. Near, K. A., A. W. Stowers, D. Jankovic, and D. C. Kaslow. 2002. Improved immunogenecity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model. Infect. Immun. 70:692-701.
31. O'Garra, A., and K. Murphy. 1994. Role of cytokines in determining T-lymphocyte function. Curr. Opin. Immunol. 6:458-466.
32. Plebanski, M., and A. Hill. 2000. The immunology of malaria infection. Curr. Opin. Immunol. 12:437-441.
33. + T lymphocytes both contribute to acquired immunity to blood-stage Plasmodium chabaudi AS. Infect. Immun. 59:51-58.
34. Sam, H., and M. M. Stevenson. 1999. In vivo IL-12 production and IL-12 receptors β1 and β2 mRNA expression in the spleen are differentially up-regulated in resistant B6 and susceptible A/J mice during early blood-stage Plasmodium chabaudi AS malaria. J. Immunol. 162:1582-1589.
35. Stacey, K. J., and J. M. Blackwell. 1999. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect. Immun. 67:3719-3726.
36. Stevenson, M. M., J. J. Lyanga, and E. Skamene. 1982. Murine malaria: genetic control of resistance to Plasmodium chabaudi. Infect. Immun. 38:80-88.
37. Stevenson, M. M., M. F. Tam, S. F. Wolf, and A. Sher. 1995. IL-12 induced protection against blood-stage Plasmodium chabaudi AS requires IFN-γ and TNF-α and occurs via an NO-dependent mechanism. J. Immunol. 155:2545-2556.
38. Stevenson, M. M., and M. F. Tam. 1993. Differential induction of helper T cell subsets during blood-stage Plasmodium chabaudi AS infection in resistant and susceptible mice. Clin. Exp. Immunol. 92:77-83.
39. Su, Z., and M. M. Stevenson. 2002. IL-12 is required for antibody-mediated protective immunity against blood-stage Plasmodium chabaudi AS malaria infection in mice. J. Immunol. 168:1348-1355.
40. Su, Z., and M. M. Stevenson. 2000. Central role of endogenous gamma interferon in protective immunity against blood-stage Plasmodium chabaudi AS infection. Infect. Immun. 68:4399-4406.
41. Taylor-Robinson, A. W., and R. S. Philips. 1994. B cells are required for the switch from TH1- to TH2-regulated immune response to Plasmodium chabaudi chabaudi infection. Infect. Immun. 62:2490-2498.
42. van der Heyde, H. C., B. Pepper, J. Batchelder, F. Cigel, and W. P. Weidanz. 1997. The time course of selected malarial infections in cytokine-deficient mice. Exp. Parasitol. 88:206-213.
43. + T cell subsets to Plasmodium chabaudi chabaudi in B cell-deficient mice. Int. Immunol. 5:1343-1348.
44. von der Weid, T., N. Honarvar, and J. Langhorne. 1996. Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection. J. Immunol. 156:2510-2516.
45. Weeratna, R. D., M. J. McCluskie, Y. Xu, and H. S. Davis. 2000. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 18:1755-1762.
46. Wynn, T. A., A. W. Cheever, D. Jankovic, R. W. Poindexter, P. Caspar, F. A. Lewis, and A. Sher. 1995. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 376:594-596.
47. Wynn, T. A., D. Jankovic, S. Hieny, A. W. Cheever, and A. Sher. 1995. IL-12 enhances vaccine-induced immunity to Schistosoma mansoni in mice and decreases T helper 2 cytokine expression, IgE production, and tissue eosinophilia. J. Immunol. 154:4701-4709.
48. Wynn, T. A., A. Reynolds, S. James, A. W. Cheever, P. Caspar, S. Hieny, D. Jankovic, M. Strand, and A. Sher. 1996. IL-12 enhances vaccine-induced immunity to schistosomes by augmenting both humoral and cell-mediated immune responses against the parasite. J. Immunol. 157:4068-4078.
49. Yap, G. S., and M. M. Stevenson. 1994. Differential requirements for an intact spleen in induction and expression of B-cell-dependent immunity to Plasmodium chabaudi AS. Infect. Immun. 62:4219-4225.